From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Verici Dx – “Commercialisation agreement with Thermo Fisher”, but still what about that cash burn?

By Steve Moore | Wednesday 15 November 2023


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Previously writing on company describing itself as “a developer of advanced clinical diagnostics for organ transplant” Verici Dx (VRCI), in July with the shares up to 12.25p I questioned how “important” was a latest step and concluded to still avoid. The shares had since fallen below 6p, but what of them currently back up to 9.5p on a “Commercialisation agreement with Thermo Fisher” announcement?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Time left: 12:20:35